So Yeon Won1, Yae Won Park2, Sung Soo Ahn1, Ju Hyung Moon3, Eui Hyun Kim3, Seok-Gu Kang3, Jong Hee Chang3, Se Hoon Kim4, Seung-Koo Lee1. 1. Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: yaewonpark@yuhs.ac. 3. Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea. 4. Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Abstract
PURPOSE: To evaluate the quality of radiomics studies on meningiomas, using a radiomics quality score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and the Image Biomarker Standardization Initiative (IBSI). METHODS: PubMed MEDLINE and Embase were searched to identify radiomics studies on meningiomas. Of 138 identified articles, 25 relevant original research articles were included. Studies were scored according to the RQS, TRIPOD guidelines, and items in IBSI. RESULTS: Only four studies (16 %) performed external validation. The mean RQS was 5.6 out of 36 (15.4 %), and the basic adherence rate was 26.8 %. The adherence rate was low for stating biological correlation (4%), conducting calibration statistics (12 %), multiple segmentation (16 %), and stating potential clinical utility (16 %). None of the studies conducted a test‒retest or phantom study, stated a comparison to a 'gold standard', conducted prospective studies or cost-effectivity analysis, or opened code and data to the public, resulting in low RQS. The overall adherence rate for TRIPOD was 54.1 %, with low scores for reporting the title (4%), abstract (0%), blind assessment of the outcome (8%), and explaining the sample size (0%). According to IBSI items, only 6 (24 %), 6 (24 %), and 3 (12 %) studies performed N4 bias-field correction, isovoxel resampling, and grey-level discretization, respectively. No study performed skull stripping. CONCLUSION: The quality of radiomics studies for meningioma is insufficient. Acknowledgement of RQS, TRIPOD, and IBSI reporting guidelines may improve the quality of meningioma radiomics studies and enable their clinical application.
PURPOSE: To evaluate the quality of radiomics studies on meningiomas, using a radiomics quality score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD), and the Image Biomarker Standardization Initiative (IBSI). METHODS: PubMed MEDLINE and Embase were searched to identify radiomics studies on meningiomas. Of 138 identified articles, 25 relevant original research articles were included. Studies were scored according to the RQS, TRIPOD guidelines, and items in IBSI. RESULTS: Only four studies (16 %) performed external validation. The mean RQS was 5.6 out of 36 (15.4 %), and the basic adherence rate was 26.8 %. The adherence rate was low for stating biological correlation (4%), conducting calibration statistics (12 %), multiple segmentation (16 %), and stating potential clinical utility (16 %). None of the studies conducted a test‒retest or phantom study, stated a comparison to a 'gold standard', conducted prospective studies or cost-effectivity analysis, or opened code and data to the public, resulting in low RQS. The overall adherence rate for TRIPOD was 54.1 %, with low scores for reporting the title (4%), abstract (0%), blind assessment of the outcome (8%), and explaining the sample size (0%). According to IBSI items, only 6 (24 %), 6 (24 %), and 3 (12 %) studies performed N4 bias-field correction, isovoxel resampling, and grey-level discretization, respectively. No study performed skull stripping. CONCLUSION: The quality of radiomics studies for meningioma is insufficient. Acknowledgement of RQS, TRIPOD, and IBSI reporting guidelines may improve the quality of meningioma radiomics studies and enable their clinical application.
Authors: Turkey Refaee; Zohaib Salahuddin; Anne-Noelle Frix; Chenggong Yan; Guangyao Wu; Henry C Woodruff; Hester Gietema; Paul Meunier; Renaud Louis; Julien Guiot; Philippe Lambin Journal: Front Med (Lausanne) Date: 2022-06-23
Authors: So Yeon Won; Jun Ho Lee; Narae Lee; Yae Won Park; Sung Soo Ahn; Jinna Kim; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Paul Windisch; Carole Koechli; Susanne Rogers; Christina Schröder; Robert Förster; Daniel R Zwahlen; Stephan Bodis Journal: Cancers (Basel) Date: 2022-05-27 Impact factor: 6.575
Authors: Lara Brunasso; Gianluca Ferini; Lapo Bonosi; Roberta Costanzo; Sofia Musso; Umberto E Benigno; Rosa M Gerardi; Giuseppe R Giammalva; Federica Paolini; Giuseppe E Umana; Francesca Graziano; Gianluca Scalia; Carmelo L Sturiale; Rina Di Bonaventura; Domenico G Iacopino; Rosario Maugeri Journal: Life (Basel) Date: 2022-04-14
Authors: Yae Won Park; Seo Jeong Shin; Jihwan Eom; Heirim Lee; Seng Chan You; Sung Soo Ahn; Soo Mee Lim; Rae Woong Park; Seung-Koo Lee Journal: Sci Rep Date: 2022-04-29 Impact factor: 4.996